Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig?s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig?s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016.
The classification of Amyotrophic Lateral Sclerosis (ALS) Treatment includes Riluzole, Edaravone (Radicava) and Other and the proportion of Edaravone (Radicava) in 2017 is about 67.7%, Radicava is approved in Japan and Korea in 2015, and through the FDA in 2017.

According to this study, over the next five years the Amyotrophic Lateral Sclerosis (ALS) Treatment market will register a 6.7% CAGR in terms of revenue, the global market size will reach US$ 330 million by 2024, from US$ 240 million in 2019. In particular, this report presents the global revenue market share of key companies in Amyotrophic Lateral Sclerosis (ALS) Treatment business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Amyotrophic Lateral Sclerosis (ALS) Treatment market by product type, application, key companies and key regions.

This study considers the Amyotrophic Lateral Sclerosis (ALS) Treatment value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Riluzole
Edaravone (Radicava)
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospital
Drugs Store
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Amyotrophic Lateral Sclerosis (ALS) Treatment market by identifying its various subsegments.
Focuses on the key global Amyotrophic Lateral Sclerosis (ALS) Treatment players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyotrophic Lateral Sclerosis (ALS) Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Amyotrophic Lateral Sclerosis (ALS) Treatment submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.